Spesolimab (Spevigo)

Key Messages

• Canada’s Drug Agency (CDA-AMC) recommends that Spevigo should be reimbursed by public drug plans for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg if certain conditions are met.
• Spevigo should only be covered to treat adults and pediatric patients aged 12 years and older, weighing at least 40 kg, and living with GPP. Spevigo should be reimbursed for both the acute treatment of GPP flares and for the prevention of GPP flares for patients with a history of flares according to the European Rare and Severe Psoriasis Expert Network (ERASPEN) criteria.
• Spevigo should only be reimbursed if prescribed by clinicians (dermatologists or rheumatologists) with expertise in managing GPP and other types of psoriasis. For the prevention of flares, the initial authorization should be for 6 months of treatment. For continued renewal of Spevigo for the prevention of flares, the severity of GPP as measured by the generalized pustular psoriasis physician global assessment (GPPGA) total score at initiation should be maintained (not worsen), patient should experience fewer flares compared to baseline, and the reduction in the number of flares should be sustained. Spevigo should only be reimbursed if there is a reduction in drug price.